Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2

Schizophrenia Research

Volumn 163, Issue 1-3, 2015, Pages 63-72

  Light, Gregory A ^a,b   Swerdlow, Neal R ^a   Thomas, Michael L ^a   Calkins, Monica E ^c   Green, Michael F ^d,e   Greenwood, Tiffany A ^a   Gur, Raquel E ^c   Gur, Ruben C ^c   Lazzeroni, Laura C ^f   Nuechterlein, Keith H ^d   Pela, Marlena ^a   Radant, Allen D ^g,h   Seidman, Larry J ^i,j   Sharp, Richard F ^a   Siever, Larry J ^k,l   Silverman, Jeremy M ^k,l   Sprock, Joyce ^a   Stone, William S ^i,j   Sugar, Catherine A ^m   Tsuang, Debby W ^g,h   Tsuang, Ming T ^a,n   Braff, David L ^a   Turetsky, Bruce I ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^f STANFORD UNIVERSITY   (United States)

^g UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^h VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l VETERANS AFFAIRS MEDICAL CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ HARVARD UNIVERSITY   (United States)

more..

Author keywords

Cognition; EEG; Function; Mismatch negativity; P300; P3a; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; ELECTROENCEPHALOGRAM; ETHNICITY; EVOKED AUDITORY RESPONSE; EXECUTIVE FUNCTION; FEMALE; FUNCTIONAL STATUS; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH NEGATIVITY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SMOKING; SOCIAL PSYCHOLOGY; VALIDATION PROCESS; ADOLESCENT; AGED; AUDITORY STIMULATION; BRAIN; CLINICAL TRIAL; COMPLICATION; ELECTROENCEPHALOGRAPHY; ENDOPHENOTYPE; EVENT RELATED POTENTIAL; FEASIBILITY STUDY; GENETICS; HEARING; MIDDLE AGED; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL RATING SCALE; REPRODUCIBILITY; SOCIOECONOMICS; VALIDATION STUDY; YOUNG ADULT;

ACOUSTIC STIMULATION; ADOLESCENT; ADULT; AGED; AUDITORY PERCEPTION; BRAIN; ELECTROENCEPHALOGRAPHY; ENDOPHENOTYPES; EVENT-RELATED POTENTIALS, P300; EVOKED POTENTIALS, AUDITORY; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SMOKING; SOCIOECONOMIC FACTORS; YOUNG ADULT;

EID: 84925879509     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.09.042     Document Type: Article

References (84)

1. Andreasen N.C. Scale for the Assessment of Negative Symptoms (SANS) 1984, University of Iowa, Iowa City.
2. Atkinson R.J., Michie P.T., Schall U. Duration mismatch negativity and P3a in first-episode psychosis and individuals at ultra-high risk of psychosis. Biol. Psychiatry 2012, 71(2):98-104.
3. Baker K., Baldeweg T., Sivagnanasundaram S., Scambler P., Skuse D. COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol. Psychiatry 2005, 58(1):23-31.
4. Baldeweg T., Klugman A., Gruzelier J., Hirsch S.R. Mismatch negativity potentials and cognitive impairment in schizophrenia. Schizophr. Res. 2004, 69(2-3):203-217.
5. Baldeweg T., Wong D., Stephan K.E. Nicotinic modulation of human auditory sensory memory: evidence from mismatch negativity potentials. Int. J. Psychophysiol. 2006, 59(1):49-58.
6. Belger A., Yucel G.H., Donkers F.C. In search of psychosis biomarkers in high-risk populations: is the mismatch negativity the one we've been waiting for?. Biol. Psychiatry 2012, 71(2):94-95.
7. Bodatsch M., Ruhrmann S., Wagner M., Muller R., Schultze-Lutter F., Frommann I., Brinkmeyer J., Gaebel W., Maier W., Klosterkotter J., Brockhaus-Dumke A. Prediction of psychosis by mismatch negativity. Biol. Psychiatry 2011, 69(10):959-966.
8. Braff D.L., Light G.A. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology 2004, 174(1):75-85.
9. Brockhaus-Dumke A., Tendolkar I., Pukrop R., Schultze-Lutter F., Klosterkotter J., Ruhrmann S. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia. Schizophr. Res. 2005, 73(2-3):297-310.
10. Calkins M.E., Dobie D.J., Cadenhead K.S., Olincy A., Freedman R., Green M.F., Greenwood T.A., Gur R.E., Gur R.C., Light G.A., Mintz J., Nuechterlein K.H., Radant A.D., Schork N.J., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Swerdlow N.R., Tsuang D.W., Tsuang M.T., Turetsky B.I., Braff D.L. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr. Bull. 2007, 33(1):33-48.
11. Catts S.V., Shelley A.M., Ward P.B., Liebert B., McConaghy N., Andrews S., Michie P.T. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am. J. Psychiatry 1995, 152(2):213-219.
12. Cohen J., Cohen P., West S.G., Aiken L.S. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences 2003, L. Erlbaum Associates, Mahwah, N.J. 3rd ed.
13. Dulude L., Labelle A., Knott V.J. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J. Clin. Psychopharmacol. 2010, 30(5):541-548.
14. Dunbar G., Boeijinga P.H., Demazieres A., Cisterni C., Kuchibhatla R., Wesnes K., Luthringer R. Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology (Berlin) 2007, 191(4):919-929.
15. Ehrlichman R.S., Maxwell C.R., Majumdar S., Siegel S.J. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J. Cogn. Neurosci. 2008, 20(8):1403-1414.
16. Engeland C., Mahoney C., Mohr E., Ilivitsky V., Knott V. Nicotine and sensory memory in Alzheimer's disease: an event-related potential study. Brain Cogn. 2002, 49(2):232-234.
17. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0) 1995, Biometrics Research Department, New York State Psychiatric Institute, New York.
18. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured clinical interview for DSM-IV Axis I Disorders - NonPatient Edition (SCID-I/NP, Version 2.0) 1996, New York State Psychiatric Institute, New York.
19. Gil-da-Costa R., Stoner G.R., Fung R., Albright T.D. Nonhuman primate model of schizophrenia using a noninvasive EEG method. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(38):15425-15430.
20. Hall M.H., Schulze K., Rijsdijk F., Picchioni M., Ettinger U., Bramon E., Freedman R., Murray R.M., Sham P. Heritability and reliability of P300, P50 and duration mismatch negativity. Behav. Genet. 2006, 36(6):845-857.
21. Hall M.H., Schulze K., Rijsdijk F., Kalidindi S., McDonald C., Bramon E., Murray R.M., Sham P. Are auditory P300 and duration MMN heritable and putative endophenotypes of psychotic bipolar disorder? A Maudsley bipolar twin and family study. Psychol. Med. 2009, 39(8):1277-1287.
22. Heaton R.K., Grant I.S., Matthews C.G. Comprehensive Norms for an Expanded Halstead-Reitan Battery: Demographic Corrections, Research Findings, and Clinical Applications 1991, Psychological Assessment Resources, Odessa, FL.
23. Hermens D.F., Ward P.B., Hodge M.A., Kaur M., Naismith S.L., Hickie I.B. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2010, 34(6):822-829.
24. Inami R., Kirino E., Inoue R., Arai H. Transdermal nicotine administration enhances automatic auditory processing reflected by mismatch negativity. Pharmacol. Biochem. Behav. 2005, 80(3):453-461.
25. Inami R., Kirino E., Inoue R., Suzuki T., Arai H. Nicotine effects on mismatch negativity in nonsmoking schizophrenic patients. Neuropsychobiology 2007, 56(2-3):64-72.
26. Jahshan C., Cadenhead K.S., Rissling A.J., Kirihara K., Braff D.L., Light G.A. Automatic sensory information processing abnormalities across the illness course of schizophrenia. Psychol. Med. 2012, 42(1):85-97.
27. Javitt D.C. When doors of perception close: bottom-up models of disrupted cognition in schizophrenia. Annu. Rev. Clin. Psychol. 2009, 5:249-275.
28. Javitt D.C., Steinschneider M., Schroeder C.E., Arezzo J.C. Role of cortical N-methyl-d-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(21):11962-11967.
29. Jessen F., Fries T., Kucharski C., Nishimura T., Hoenig K., Maier W., Falkai P., Heun R. Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neurosci. Lett. 2001, 309(3):185-188.
30. Kawakubo Y., Kasai K., Kudo N., et al. Phonetic mismatch negativity predicts verbal memory deficits in schizophrenia. NeuroReport. 2006, 17:1043-1046.
31. Kawakubo Y., Kamio S., Nose T., Iwanami A., Nakagome K., Fukuda M., Kato N., Rogers M.A., Kasai K. Phonetic mismatch negativity predicts social skills acquisition in schizophrenia. Psychiatry Res. 2007, 152(2-3):261-265.
32. Kiang M., Braff D.L., Sprock J., Light G.A. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin. Neurophysiol. 2009, 120(11):1949-1957.
33. Kirihara K., Rissling A.J., Swerdlow N.R., Braff D.L., Light G.A. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol. Psychiatry 2012, 71(10):873-880.
34. Kirino E., Inoue R. The relationship of mismatch negativity to quantitative EEG and morphological findings in schizophrenia. J. Psychiatr. Res. 1999, 33(5):445-456.
35. Lavoie S., Murray M.M., Deppen P., Knyazeva M.G., Berk M., Boulat O., Bovet P., Bush A.I., Conus P., Copolov D. Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 2007, 33(9):2187-2199.
36. Light G.A., Braff D.L. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch. Gen. Psychiatry. 2005, 62(2):127-136.
37. Light G.A., Braff D.L. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am. J. Psychiatry. 2005, 162(9):1741-1743.
38. Light G.A., Näätänen R. Mismatch negativity is a breakthrough biomarker for understanding and treating psychotic disorders. Proc. Natl. Acad. Sci. 2013, 110(38):15175-15176.
39. Light G.A., Swerdlow N.R. Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle. Curr. Top. Behav. Neurosci. 2014.
40. Light G.A., Hsu J.L., Hsieh M.H., Meyer-Gomes K., Sprock J., Swerdlow N.R., Braff D.L. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol. Psychiatry 2006, 60(11):1231-1240.
41. Light G.A., Swerdlow N.R., Braff D.L. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J. Cogn. Neurosci. 2007, 19(10):1624-1632.
42. Light, G.A., Williams, L.E., Minow, F., Sprock, J., Rissling, A., Sharp, R., Swerdlow, N.R., Braff, D.L., 2010. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Current protocols in neuroscience/editorial board, Jacqueline N. Crawley.. [et al.] Chapter 6, Unit 6 25 21-24.
43. Light G.A., Swerdlow N.R., Rissling A.J., Radant A., Sugar C.A., Sprock J., Pela M., Geyer M.A., Braff D.L. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One 2012, 7(7):e39434.
44. Light G., Greenwood T.A., Swerdlow N.R., Calkins M.E., Freedman R., Green M.F., Gur R.E., Gur R.C., Lazzeroni L.C., Nuechterlein K.H., Olincy A., Radant A.D., Seidman L.J., Siever L.J., Silverman J.M., Sprock J., Stone W.S., Sugar C.A., Tsuang D.W., Tsuang M.T., Turetsky B.I., Braff D.L. Comparison of the heritability of schizophrenia and endophenotypes in the COGS-1 family study. Schizophr. Bull. 2014.
45. Martin L.F., Davalos D.B., Kisley M.A. Nicotine enhances automatic temporal processing as measured by the mismatch negativity waveform. Nicotine Tob. Res. 2009, 11(6):698-706.
46. Maxwell M.E. Manual for the FIGS 1992, Clinical Neurogenetics Branch, National Institute of Mental Health, Bethesda (MD).
47. McPheeters H.L. Statewide mental health outcome evaluation: a perspective of two southern states. Community Ment. Health J. 1984, 20(1):44-55.
48. Michie P.T. What has MMN revealed about the auditory system in schizophrenia?. Int. J. Psychophysiol. 2001, 42(2):177-194.
49. Michie P., Innes-Brown H., Todd J., Jablensky A. Duration mismatch negativity in biological relatives of patients with schizophrenia spectrum disorders. Biol. Psychiatry 2002, 52(7):749-758.
50. Näätänen R. The role of attention in auditory information processing as revealed by event-related potentials and other brain measures of cognitive function. Behav. Brain Sci. 1990, 13(02):201-233.
51. Naatanen R. Attention and Brain Function 1992, Lawrence Erlbaum Associates, Inc., Hillsdale, NJ.
52. Naatanen R., Paavilainen P., Alho K., Reinikainen K., Sams M. Do event-related potentials reveal the mechanism of the auditory sensory memory in the human brain?. Neurosci. Lett. 1989, 98(2):217-221.
53. Näätänen R., Kujala T., Kreegipuu K., et al. The mismatch negativity: an index of cognitive decline in neuropsychiatric and neurological diseases and in ageing. Brain: J. Neurol. 2011, 134(Pt 12):3435-3453.
54. Nagai T., Tada M., Kirihara K., Araki T., Jinde S., Kasai K. Mismatch negativity as a "translatable" brain marker toward early intervention for psychosis: a review. Front. Psychiatry 2013, 4:115.
55. Nagai T., Tada M., Kirihara K., Yahata N., Hashimoto R., Araki T., Kasai K. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis. Schizophr. Res. 2013, 150(2):547-554.
56. Nakamura T., Michie P.T., Fulham W.R., Todd J., Budd T.W., Schall U., Hunter M., Hodgson D.M. Epidural auditory event-related potentials in the rat to frequency and duration deviants: evidence of mismatch negativity?. Front. Psychol. 2011, 2:367.
57. Norman M.A., Moore D.J., Taylor M., Franklin D., Cysique L., Ake C., Lazarretto D., Vaida F., Heaton R.K., Group H. Demographically corrected norms for African Americans and Caucasians on the Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised, Stroop Color and Word Test, and Wisconsin Card Sorting Test 64-Card Version. J. Clin. Exp. Neuropsychol. 2011, 33(7):793-804.
58. Oades R.D., Wild-Wall N., Juran S.A., Sachsse J., Oknina L.B., Ropcke B. Auditory change detection in schizophrenia: sources of activity, related neuropsychological function and symptoms in patients with a first episode in adolescence, and patients 14years after an adolescent illness-onset. BMC Psychiatry 2006, 6:7.
59. Oknina L.B., Wild-Wall N., Oades R.D., Juran S.A., Ropcke B., Pfueller U., Weisbrod M., Chan E., Chen E.Y. Frontal and temporal sources of mismatch negativity in healthy controls, patients at onset of schizophrenia in adolescence and others at 15years after onset. Schizophr. Res. 2005, 76(1):25-41.
60. Patterson T.L., Goldman S., McKibbin C.L., Hughs T., Jeste D.V. UCSD performance-based skills assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr. Bull. 2001, 27(2):235-245.
61. Perez V.B., Swerdlow N.R., Braff D.L., Näätänen R. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark. Med 2014, 8(1):9-14.
62. Perez V.B., Woods S.W., Roach B.J., Ford J.M., McGlashan T.H., Srihari V.H., Mathalon D.H. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol. Psychiatry 2014, 75(6):459-469.
63. Preskorn S.H., Gawryl M., Dgetluck N., Palfreyman M., Bauer L.O., Hilt D.C. Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J. Psychiatr. Pract. 2014, 20(1):12-24.
64. Price G.W., Michie P.T., Johnston J., Innes-Brown H., Kent A., Clissa P., Jablensky A.V. A multivariate electrophysiological endophenotype, from a unitary cohort, shows greater research utility than any single feature in the Western Australian family study of schizophrenia. Biol. Psychiatry 2006, 60(1):1-10.
65. Rapaport M.H., Bazzetta J., McAdams L.A., Patterson T., Jeste D.V. Validation of the scale of functioning in older outpatients with schizophrenia. Am. J. Geriatr. Psychiatr. 1996, 4(3):218-228.
66. Rasser P.E., Schall U., Todd J., et al. Gray matter deficits, mismatch negativity, and outcomes in schizophrenia. Schizophr. Bull. 2011, 37:131-140.
67. R Development Core Team R: A language and environment for statistical computing 2011, R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0, http://www. R-project.org.
68. Rissling A.J., Makeig S., Braff D.L., Light G.A. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr. Psychiatry Rep. 2010, 12(6):572-578.
69. Rissling A.J., Braff D.L., Swerdlow N.R., Hellemann G., Rassovsky Y., Sprock J., Pela M., Light G.A. Disentangling early sensory information processing deficits in schizophrenia. Clin. Neurophysiol. 2012, 123(10):1942-1949.
70. Rissling A.J., Park S.H., Young J.W., Rissling M.B., Sugar C.A., Sprock J., Mathias D.J., Pela M., Sharp R.F., Braff D.L., Light G.A. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr. Res. 2013, 146(1-3):326-335.
71. Rissling A.J., Park S.-H., Young J.W., Rissling M.B., Sugar C.A., Sprock J., Mathias D.J., Pela M., Sharp R.F., Braff D.L. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr. Res. 2013, 146(1-3):326-335.
72. Rissling A.J., Miyakoshi M., Sugar C.A., Braff D.L., Makeig S., Light G.A. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014, (in press).
73. Salisbury D.F., Shenton M.E., Griggs C.B., Bonner-Jackson A., McCarley R.W. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch. Gen. Psychiatry 2002, 59(8):686-694.
74. Schreiber H., Stolz-Born G., Kornhuber H.H., Born J. Event-related potential correlates of impaired selective attention in children at high risk for schizophrenia. Biol. Psychiatry 1992, 32(8):634-651.
75. Shelley A.M., Ward P.B., Catts S.V., Michie P.T., Andrews S., McConaghy N. Mismatch negativity: an index of a preattentive processing deficit in schizophrenia. Biol. Psychiatry 1991, 30:1059-1062.
76. Shinozaki N., Yabe H., Sato Y., Hiruma T., Sutoh T., Nashida T., Matsuoka T., Kaneko S. The difference in mismatch negativity between the acute and post-acute phase of schizophrenia. Biol. Psychol. 2002, 59(2):105-119.
77. Swerdlow N.R., Light G.A., Sprock J., Calkins M.E., Green M.F., Greenwood T.A., Gur R.E., Gur R.C., Lazzeroni L.C., Nuechterlein K.H., Radant A.D., Ray A., Seidman L.J., Siever L.J., Silverman J.M., Stone W.S., Sugar C.A., Tsuang D.W., Tsuang M.T., Turetsky B.I., Braff D.L. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr. Res. 2015, 152(2-3):503-512.
78. Swerdlow N.R., Gur R., Braff D.L. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this special issue of schizophrenia research. Schizophr. Res. 2014, 163(1-3):9-16. (in press).
79. Takahashi H., Rissling A.J., Pascual-Marqui R., Kirihara K., Pela M., Sprock J., Braff D.L., Light G.A. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. NeuroImage 2012, 66C:594-603.
80. Umbricht D., Krljes S. Mismatch negativity in schizophrenia: a meta-analysis. Schizophr. Res. 2005, 76(1):1-23.
81. Umbricht D., Schmid L., Koller R., Vollenweider F.X., Hell D., Javitt D.C. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000, 57(12):1139-1147.
82. Umbricht D., Koller R., Vollenweider F.X., Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 2002, 51(5):400-406.
83. Umbricht D.S., Bates J.A., Lieberman J.A., Kane J.M., Javitt D.C. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol. Psychiatry 2006, 59(8):762-772.
84. Wynn J.K., Sugar C., Horan W.P., et al. Mismatch negativity, social cognition, and functioning in schizophrenia patients. Biol. Psychiatry. 2010, 67:940-947.